- Home
- WETO vs FBRX Comparison
WETO vs FBRX Comparison
Compare WETO & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WETO
- FBRX
- Stock Information
- Founded
- WETO 2019
- FBRX N/A
- Country
- WETO China
- FBRX United States
- Employees
- WETO N/A
- FBRX N/A
- Industry
- WETO
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- WETO
- FBRX Health Care
- Exchange
- WETO NYSE
- FBRX Nasdaq
- Market Cap
- WETO 88.0M
- FBRX 80.6M
- IPO Year
- WETO 2025
- FBRX N/A
- Fundamental
- Price
- WETO $2.57
- FBRX $12.53
- Analyst Decision
- WETO
- FBRX Strong Buy
- Analyst Count
- WETO 0
- FBRX 2
- Target Price
- WETO N/A
- FBRX $61.00
- AVG Volume (30 Days)
- WETO 2.1M
- FBRX 75.1K
- Earning Date
- WETO 01-01-0001
- FBRX 08-13-2025
- Dividend Yield
- WETO N/A
- FBRX N/A
- EPS Growth
- WETO N/A
- FBRX N/A
- EPS
- WETO N/A
- FBRX N/A
- Revenue
- WETO $5,350,773.00
- FBRX N/A
- Revenue This Year
- WETO N/A
- FBRX N/A
- Revenue Next Year
- WETO N/A
- FBRX N/A
- P/E Ratio
- WETO N/A
- FBRX N/A
- Revenue Growth
- WETO N/A
- FBRX N/A
- 52 Week Low
- WETO $1.50
- FBRX $4.11
- 52 Week High
- WETO $4.30
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- WETO N/A
- FBRX 63.13
- Support Level
- WETO N/A
- FBRX $11.36
- Resistance Level
- WETO N/A
- FBRX $13.74
- Average True Range (ATR)
- WETO 0.00
- FBRX 0.94
- MACD
- WETO 0.00
- FBRX 0.09
- Stochastic Oscillator
- WETO 0.00
- FBRX 77.68
About WETO WEBUS INTERNATIONAL LIMITED
Webus International Ltd operates on a business model of Mobility-as-a-Service to identify and solve inefficiencies associated with inflexible or low-quality public transportation and provide cost-efficient and customized mass transportation services under different scenarios with comprehensive digital platforms. It offers commute shuttle service, customized chartered bus service, packaged tour service and other service to customers.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).